Krishan Maggon’s Registered & Protected Web Page

My profile▼ | Help | Sign outSign in 
          












Search Toolkit










Krishan MaggonVerify NameConsultant Pharmaceutical Biotechnology R&D  & AdvisorGeneva, Switzerland & New York, USA Public activity feed
 

International pharma executive with a successful track record in new drug development, project management, business development, licensing, market introduction/support, contract and external research management and training. Established leadership skills and ability to get results. Extensive contacts with key scientific, medical and technical academic and industrial leaders worldwide. Doctorate in Medical Biochemistry, over 100 publications. Consultancy and Advisor, New Drug Development and Consultancy in New Drug Development, Licensing and Technology Transfer.Selected Publications Maggon  K.  List of Publications Dealing with Drug Development      Publications 1-32 dealt with academic research on biosynthesis of aflatoxins   33. Aspects of clinical pharmacology and bioavailability of Azapropazone in              "Azapropazone - 20 Years of Clinical Use", Edited by KD Rainsford, Kluwer academic              publishers, Lancaster, U.K., 1989.   34. Immunology, Past, Present and Future. Immunology from Research to              Profits, Düsseldorf, Germany, 1989.   38. Oral administration of DuP 753, a specific angiotensin II antagonist to normal volunteers. Circulation 83:1333-1342, 1991.   41. Interaction of Cimetidine with Nsaids. XIIth European Congress of Rheumatology, Budapest, July 1991.   43. Development of antifungal agents by the pharmaceutical industry. Drugs of Today 27:317-330, 1991.   46. WHO  GLP Guidelines. Ist Draft. 1991.WHO, Geneva   49.       Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of                     the blood-brain barrier: Elucidation by the action of the immunosuppressant              Brequinar Sodium. J Neurology  38:53-62,1992.   50. Total Quality Management in the Pharmaceutical Industry.              Drug News and Perspectives 5:261-270,1992   51.Total  Complex Quality Management for drugs in              the area of research, development and initial manufacturing .              (In Russian). Himiko-Farmaceutical Zurnal ( Moscow) no 4, 4-10, 1993.   55. Standard operating procedures and the conduct of clinical trials.              Appl.Clin. Trials 3, 46-49, 1994.   56. Immunosuppressive gold rush and drug development. Drug News and Perspectives             7, 389-401, 1994.    57. Medical uses of sulfur hexafluoride. Drugs of the Future 19, 1101-1107, 1994   58. Linking research strategies to market opportunities in development of               cardiovascular drugs. Drug News and Perspectives 8, 560-571, 1995.   59. Discovery and development of losartan,an orally active angiotensin II receptor antagonists. Abstracts International Symposium of Trends in Life Sciences. Jawaharlal Nehru University, New Delhi, India. Dec. 17-19, 1997   60. New Drug Development for Alzheimer’s Disease. Abstracts International Symposium of Trends in Life Sciences. Jawaharlal Nehru University, New Delhi, India. Dec. 17-19, 1997   61. Ayurveda. Abstract of Symposium on Medicine and Ethics, Davos, February 4-5, 1998   62. Risk Benefit Assessment of Glitazones. Express Pharma Pulse. Mumbai. September 12, 2002.    63. Ups and down in drug development. Express Pharma Pulse. Mumbai. October 3, 2002.  Express Healthcare Management Mumbai, October 16, 2002.    64. Activated Protein C  in treating sepsis. Express Pharma Pulse, Mumbai  February 27, 2003, Express Healthcare Management Mumbai, March 1, 2003   65. Risk  benefit assessment of APC. Express Pharma Pulse, Mumbai . March 6,  2003. Express Healthcare Management Mumbai, April 1, 2003   66. New Drug Discovery and Development in India. Drug News and Perspectives. Prous Science, Barcelona. 16(Supplement) .March  2003, 1-19. 67. Hepatotoxicity of Nefazadone. Express Pharma Pulse. Mumbai, 15 May, 2003.   68. Setting new standards in drug safety. Nefazodone and hepatotoxicity – II. Express Pharma Pulse, Mumbai, India. 22 May 2003.   69. New Drug Discovery and Development in India. Drug News and Perspectives. 16(Supplement), 1-19, March 2003.70. A passage to India. Good Clinical Practice Journal, 10, 29-32, 2003. PJB Publications, UK. 71. The ten billion dollar molecule. Pharmaceutical Executive. 2003; 23: 60-68.    72. The future of the research based pharmaceutical industry. Editorial Express Pharma Pulse. January 29, 2004.     73. Rise of biologicals. Editorial Express Pharma Pulse. February 5, 2004.       74. Clinical studies with new drugs: My Indian Experiences. Express Pharma Pulse. March 4, 2004.   Express Health Care Management March 15-30, 2004.   75. Revisiting Nimesulide marketing in India. Chronicle Pharmabiz., Mumbai March 18, 25 and April 1, 2004    76. Role of Contract Research Organizations in new drug development. Express Pharma Pulse. March 25, 2004.    77. Stained statin Rosuvastatin. Express Pharma Pulse April 1, 2004.    78. Marketing of medicines in India. Essential Drugs, WHO. April 15, 2004.  bmj.bmjjournals.com/cgi/eletters/328/7443/778    79. Unethical promotion in india. Rosuvastatin. Express Pharma Pulse April 8, 2004.    80. New Drugs and treatment for respiratory syncytial virus.  Reviews in Molecular Virology 14,149-168, 2004.    81. Setting new standards about drug safety. .Express Pharma Pulse 22 May 2004.    82. Safety Concerns about low dose rosuvastatin.  Express Health Care Management. June 1-15, 2004.   83. Toxicology Testing in India for medicinal products. Express Pharma Pulse.  Pharma Reseach Special  Issue, July 29, 2004, Mumbai, India.    84. Site and Investigator Selection for global Phase II-III trials in India. Controlled Clinical Trials.25, 366-377, 2004.    85. Generic Drug Approvals in the USA and Europe. Express Pharma Pulse. September 2, 2004.    86. Waiting for Generic Atorvastatin. Express Pharma Pulse. September 16, 2004.    87. Maggon K. Regulatory reforms and GCP Clinical Trials with New Drugs in India. Clinical Trials. 1/5,1-7, 2004.   88. Maggon K. Shock and pain after rofecoxib. Express pharma Pulse 21 October    2004.    89. Maggon K. Rofecoxib (Vioxx) and Cardiovascular Risk.  Express Healthcare Management. 1st-15th November, 2004.  Express Pharma Pulse 4 November, 2004.    90. Cardiotoxicity of Selective COX II Inhibitors. Express Pharma Pulse. 25th November, 2004.    91.  Impact of Vioxx withdrawal on pharma R&D. Medicine and Biotech.com. 15 November, 2004.    92. Swiss voters back stem cell research under strict conditions. Medicine and Biotech.com. 15 December, 2004.    93. Proteomic Bailout : The end of Gene Prot. . Medicine and Biotech.com. 15 March, 2005.    94. A case for lower dose of Rosuvastatin (Crestor). Express Pharma Pulse. March 17, 2005   95. The Statin War. Express Pharma Pulse. April 21, 2005.    96. Biotech segment: Moving ahead of pharmaceutical industry. Express Pharma Pulse. April 28, 2005.   97. Best Selling Human Medicines 2002-2004. Drug Discovery Today  2005, 10: 738-742.   98. Supply of study drug. Can. Med. Assoc. J. 2006.   99.  Market Intelligence and Pharma Data Mining.  http://www.medicineandbiotech.com.  e-Published, Feb 1st, 2007   100. Overview of the pharmaceutical & biotechnology industry Performance in 2006. http://www.medicineandbiotech.com.  e-Published, March 1st, 2007   101. Monoclonal Antibody “Gold Rush”. Current Medicinal Chemistry  2007, 14, 1978-1987.    102. Commercial success defines the future R&D trends for biologics Handbook of Pharmaceutical Biotechnology Editor Gad S. Wiley and Sons. May 2007, pp 161-200.                Sort by:last modifiedcreation datepage viewsalphabeticalCompactShow results that are:PublishedUnpublishedResults 1-20 of about 44High Priced Prescription DrugsViews: 302Published version: 32Edited: 5 hours agoNanoMedicine, Biotechnology & Nanotechnology?Views: 66Comments: 1Published version: 12Edited: 5 hours agoKnol Citation Goes MainstreamViews: 202Comments: 3Published version: 26Edited: 6 hours agoCommercial Abuse of  Copyright Protected KnolsViews: 138Comments: 2Published version: 28Edited: 6 hours agoPharmaceutical and Biotechnology Industry Overview 2008Views: 202Published version: 24Edited: 6 hours agoHealthcare CostsViews: 25Comments: 3Published version: 33Edited: 7 hours agoGlobal Pharmaceutical Market Review & World Top Ten/Twenty Drugs 2008Views: 4335Comments: 2Published version: 99Edited: One day agoThe Who's Who of KnolViews: 328Comments: 10Published version: 47Edited: 2 days agoPlagiarism on Knol? Report it Here!Views: 605Comments: 27Published version: 67Edited: 3 days agoThe Curious Case of Randy KViews: 521Comments: 8Published version: 15Edited: 4 days agoBiotechnology Global Market Intelligence MonographViews: 12Published version: 5Edited: 5 days agoPharma Global Market Segment Intelligence MonographViews: 10Published version: 6Edited: 6 days agoGlobal Market Intelligence Overview Monograph 2009Views: 1944Comments: 1Published version: 31Edited: 6 days agoGlobal Biologic Market Review & Top Ten Biologics 2008Views: 1062Published version: 39Edited: May 8, 2009 1:41 AMGlobal Vaccine Market Review 2008 (World Top Ten Vaccines)Views: 1462Comments: 1Published version: 32Edited: May 8, 2009 1:39 AMPublishing in knol vs Biomedical JournalsViews: 388Comments: 3Published version: 49Edited: May 7, 2009 9:35 AMSuper KnolsViews: 413Comments: 14Published version: 45Edited: May 7, 2009 9:18 AMGlobal Biotechnology Market Review & World Top Ten Biotech Drugs 2008Views: 1773Comments: 2Published version: 58Edited: May 6, 2009 10:56 PMKnol Site Metrics Reveal Good, Bad & UglyViews: 2083Comments: 114Published version: 223Edited: May 6, 2009 12:31 PMGlobal Angiotensin II Receptor Antagonists Market Review 2008Views: 778Published version: 38Edited: May 6, 2009 12:25 PM 1023NextReviews by this authorReviews about this author's knolsSort by:last modifiedcreation datepage viewsalphabeticalCompactShow results that are:PublishedUnpublishedResults 1-4 of about 4Review of Science 2.0Published version: 2Edited: Apr 25, 2009 11:53 AMReview of What can Nanotechnology learn from Biotechnology?Published version: 9Edited: Apr 21, 2009 1:40 AMReview of Interleukin 27 and its potential role in human sepsisPublished version: 3Edited: Apr 13, 2009 5:25 AMReview of Chemistry DemosPublished version: 2Edited: Apr 13, 2009 5:12 AMComments by this authorComments written to this authorResults 1-10 of about 201Health Advice Contrary to Official Guidelines? byKrishan MaggonIf some readers like to ignore official CDC/WHO health expert advice at their own risk, it is their choice? Your advice ...Edited: 4 hours agoMisleading and DangerousbyKrishan MaggonI do not know how many patients your advice is going to kill but to steer away infected swine flu patients away from the o...Edited: One day agoGreat and lucid description:  5 starsbyKrishan MaggonCyril,I hope your next articles deal with cognitive functions and review of MRI in Alzheimer's and Parkinson Diseases....Edited: 3 days ago5 stars and great workbyKrishan MaggonIt has started working for me as well and look I can use it to track down to the city of commercial free riders of my work...Edited: 3 days agoUntitledbyKrishan MaggonRoger, Thanks for your prompt action in deleting my reference from your adverts. Have you done the same from the report as...Edited: 3 days agoCancel or block Star ratingsbyKrishan MaggonIs it possible for authors to delete or block star ratings from work in progress type of knols?One of my unfinished knol ...Edited: 3 days agoKnol Algorithm ParadoxbyKrishan MaggonGoogle and Knol data analysis and stats driven approach sometimes leads to misleading results. I doubt if it can ever pick...Edited: 3 days agoGreat content needs reorganization byKrishan MaggonThis is a good collection of patents and slides presentations. I have given it a 5 star rating with the hope that it can b...Edited: 5 days agoUntitledbyKrishan MaggonThis knol is based on facts and driven by evidence. There are other boards in knol where  junk science is discussed and ...Edited: 5 days agoData analysisbyKrishan MaggonDamien, Can you provide me a guide, some references (pdf) or how to type of manual to look at data available in the publ...Edited: 5 days ago 102345678910NextNo results foundResults 1-10 of about 10ManuelViews: 12619Comments: 104Joined: Aug 13, 2008 2:30 PMAlexandre GouveiaMD, GP Trainee, Viana do CasteloViews: 2318Joined: Jan 5, 2009 2:51 PMCarlos Vázquez PérezMédico, PhysicianViews: 8543Comments: 16Joined: Dec 29, 2008 11:22 AMDr Neil FlanaganManagement Strategist, AustraliaViews: 12113Comments: 4Joined: Aug 31, 2008 7:01 PMLisa MurraySmall Business Coach, Peak Performance Strategist, Brisbane, AustraliaViews: 1626Joined: Sep 8, 2008 11:10 PMMurry ShohatJournalist, freelance writer, editor and strategic marketing consultant, Wine countryViews: 20735Comments: 186Joined: Jul 24, 2008 6:46 PMPeter BaskervilleCourse Facilitator - Entrepreneurship Education, AustraliaViews: 53480Comments: 386Joined: Aug 6, 2008 4:41 AMSamuel BarrackNeurologist, SouthamptonViews: 2318Joined: Dec 31, 2008 7:55 AMTiago VillanuevaGP trainee/Family Medicine resident, Lisbon, PortugalViews: 2318Joined: Jan 6, 2009 8:13 AMTrudy RobinsonRecords Management Architect, BrisbaneViews: 4231Comments: 3Joined: Sep 21, 2008 6:01 PM







Edit this knolWrite a knolActivity for this author's knolsThis week:12commentsTotals:200commentsAuthor's awardsTop Viewed Author AwardTop Pick Author Award Krishan Maggon on the webMy biohttp://knol.google.com/k/krishan-maggon/pharmaceutical-and-biotechnology/3fy5eowy8suq3/4#http://knol.google.com/k/krishan-maggon/-/3fy5eowy8suq3/0#knolsAuthor's statisticsAuthor since: Jul 24, 2008 5:48 AMLast active: May 15, 2009 5:20 AM







Home
           | 
          Terms of Service
           | 
          Privacy Policy
           | 
          Content Policy

           | 
          Help

©2009 Google